This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2026
Grand Nikko Tokyo DaibaTokyo

Dr. Lei Qian, MD, PhD
Chief R&D Officer, General Biomedicine at Innoventbio
Speaker

Profile

Dr. Lei Qian serves as Chief R&D Officer at Innoventbio. A board-certified endocrinologist with prior clinical practice at a teaching hospital, Dr. Qian brings 15 years of expertise in clinical development and medical affairs, specializing in metabolic diseases, immunology, and ophthalmology. He has successfully led the development of over 12 therapeutic assets, including four that achieved regulatory approval in China.

Agenda Sessions

  • Clinical Development of Mazdutide, the First Dual GCG/GLP-1 Receptor Agonist Approval in China, for Chronic Weight Management

    4:30pm